Kymera gains Fast Track status for oral candidate KT-621 for eczema

 Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial 

KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 

https://www.biospace.com/press-releases/kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-atopic-dermatitis